World's Best Scientists 2026 revealed!
Bernard Escudier

Bernard Escudier

Award Badge
Medicine
France
2023

D-Index & Metrics

Medicine

D-Index
127
Citations
95426
World Ranking
2762
National Ranking
70

Research.com Recognitions

  • 2023 - Research.com Medicine in France Leader Award

Overview

Bernard Escudier is affiliated with the Institut Gustave Roussy in France and focuses primarily on medical research related to oncology and renal cell carcinoma treatment. Their work intersects several fields of study, most notably Medicine, Biochemistry, Genetics and Molecular Biology, with specific emphasis on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, and Molecular Biology.

Their research covers key topics such as renal cell carcinoma treatment, cancer immunotherapy and biomarkers, cancer genomics and diagnostics, as well as the economic and financial impacts of cancer. They have also contributed to studies on renal and related cancers, pancreatic and hepatic oncology research, and bladder and urothelial cancer treatments.

The scientist has published extensively in frequent publication venues, including:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • European Journal of Cancer
  • European Urology
  • Journal for ImmunoTherapy of Cancer

Recent significant papers authored or coauthored by Bernard Escudier include:

  • "Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma" (2021), New England Journal of Medicine
  • "Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade" (2020), Cancer Cell
  • "Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage" (2020), Science
  • "Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients" (2020), European Urology
  • "Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial" (2020), Cancer

Bernard Escudier collaborates frequently with several coauthors, including Laurence Albigès, Robert J. Motzer, Camillo Porta, David F. McDermott, and Ronan Flippot.

Best Publications

  • Sorafenib in advanced clear-cell renal-cell carcinoma.

    Bernard Escudier;Tim Eisen;Walter M. Stadler;Cezary Szczylik

  • Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

    Robert J. Motzer;Bernard Escudier;David F. McDermott;Saby George

  • Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

    Robert J Motzer;Nizar M Tannir;David F McDermott;Osvaldo Arén Frontera

  • Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

    Robert J Motzer;Bernard Escudier;Stéphane Oudard;Thomas E Hutson

  • Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

    Bernard Escudier;Anna Pluzanska;Piotr Koralewski;Alain Ravaud

  • Renal cell carcinoma

    Brian I Rini;Steven C Campbell;Bernard Escudier

  • Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

    Brian I. Rini;Bernard Escudier;Piotr Tomczak;Andrey Kaprin

  • Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    B. Escudier;C. Porta;M. Schmidinger;N. Rioux-Leclercq

  • Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.

    Robert J. Motzer;Bernard Escudier;Stephane Oudard;Thomas E. Hutson

  • Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial

    Bernard Escudier;Thierry Dorval;Nathalie Chaput;Fabrice André

  • Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

    Bernard Escudier;Tim Eisen;Walter M. Stadler;Cezary Szczylik

  • Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

    Toni K. Choueiri;Thomas Powles;Mauricio Burotto;Bernard Escudier

  • Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

    Toni K. Choueiri;Bernard Escudier;Thomas Powles;Paul N. Mainwaring

  • Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma

    Sylvie Negrier;Bernard Escudier;Christine Lasset;Jean-Yves Douillard

  • CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner

    Francois Ghiringhelli;Cédric Ménard;Magali Terme;Caroline Flament

  • Malignant effusions and immunogenic tumour-derived exosomes

    Fabrice Andre;Noel E C Schartz;Mojgan Movassagh;Caroline Flament

  • Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

    Brian I Rini;Thomas Powles;Michael B Atkins;Bernard Escudier

  • Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

    David F. McDermott;Mahrukh A. Huseni;Michael B. Atkins;Robert J. Motzer

  • Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival

    Bernard Escudier;Joaquim Bellmunt;Sylvie Négrier;Emilio Bajetta

  • Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

    Toni K Choueiri;Bernard Escudier;Thomas Powles;Nizar M Tannir

Frequent Co-Authors

Laurence Albiges
Laurence Albiges Institut Gustave Roussy
Robert J. Motzer
Robert J. Motzer Memorial Sloan Kettering Cancer Center
Alain Ravaud
Alain Ravaud University of Bordeaux
Brian I. Rini
Brian I. Rini Vanderbilt University Medical Center
Camillo Porta
Camillo Porta University of Bari Aldo Moro
Thomas Powles
Thomas Powles Queen Mary University of London
Toni K. Choueiri
Toni K. Choueiri Harvard University
Karim Fizazi
Karim Fizazi University of Paris-Saclay
David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center
Stéphane Oudard
Stéphane Oudard Hôpital Européen Georges-Pompidou

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in medicine opens doors to a wide range of related fields and advanced degrees. Many students consider healthcare leadership roles by enrolling in the cheapest mha programs online healthcare options. These programs can prepare future administrators to manage hospitals and healthcare organizations.

Nurses looking to take on clinical leadership or academic roles often turn to cheap online dnp programs to achieve a terminal degree in their field. If your interests lie more in the pharmaceutical sector, pursuing a 3-year online pharmd can help fast-track your career as a licensed pharmacist.

For those who want to focus on the intersection of technology and healthcare, a health information management degree online offers opportunities in data management, electronic health records, and medical informatics.

Exploring these affordable online degrees allows students and professionals to tailor their educational paths in medicine and healthcare, helping them reach specialized career goals beyond the traditional MD.

Best Scientists Citing Bernard Escudier

Trending Scientists

Recently Published Articles